Jiangsu Hengrui’s 30 B RMB Share‑Buyback Boosts China Biopharma Growth
Jiangsu Hengrui’s aggressive share‑buyback and China’s new biopharma reimbursement reforms signal a growing investor confidence, positioning the company for robust growth and value creation amid supply‑chain resilience and regulatory evolution.
4 minutes to read